NCT07059741View on ClinicalTrials.gov

Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

December 10, 2028

Study Completion Date

December 10, 2028

Conditions
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Interventions
OTHER

integrated low-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T

"1. RT regimen:~ localized low dose RT: 1-1.5Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~ * Simustine 250mg/m2 d-6 orally~ * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~ * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~ * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~ * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~ * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"

OTHER

integrated high-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T

"1. RT regimen:~ localized high dose RT: 3-6Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~ * Simustine 250mg/m2 d-6 orally~ * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~ * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~ * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~ * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~ * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"

Trial Locations (1)

215006

RECRUITING

the First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER